Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00671710 · ClinicalTrials.gov registry record · Phase 1
Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain
A Phase 1 study, sponsored by Advocate Hospital System.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00671710: Completed Phase 1 study, sponsored by Advocate Hospital System.
NCT00671710 is a Phase 1 study that has completed, run by Advocate Hospital System. The registered enrollment target is 26 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00671710, a Phase 1 study, has completed, sponsored by Advocate Hospital System.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Tumors of the central nervous system are potentially curable. For tumors of comparable histology and grade, resectability is the most important prognostic factor affecting survival particularly in children. However, the infiltrative nature of the malignant cells produces indistinct borders between normal and malignant tissues, and the lack of easily identifiable tumor margins confounds attempts toward total resection. The investigators propose to identify the borders of tumors intraoperatively using protoporphyrin fluorescence of the malignant cells and thereby provide more complete tumor resection.
Interventions
- DRUG Aminolevulinic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-04 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT00671710 record still lists
NCT00671710 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (57% lower).
The record links to 0 conditions, and to 1 intervention - of which Aminolevulinic Acid is the first listed.
NCT00671710 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00671710 about?
NCT00671710 is a clinical study titled "Study of Aminolevulinic Acid to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain". Tumors of the central nervous system are potentially curable. For tumors of comparable histology and grade, resectability is the most important prognostic factor affecting survival particularly in children. However, the infiltrative nature of the malignant cells produces indistinct borders between n...
What is the current status of trial NCT00671710?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2008-04. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00671710?
The interventions under investigation include: Aminolevulinic Acid (DRUG).
Who is sponsoring clinical trial NCT00671710?
This trial is sponsored by Advocate Hospital System, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00671710's enrollment target sits among peer trials
26 1482nd of 2000 higher than 506 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia